131 related articles for article (PubMed ID: 1394337)
1. Phase I trial of ImuVert (natural membrane vesicles associated with ribosomes) in patients with advanced cancer.
Mittelman A; Urban R; Wong G; Ahmed T; Arlin Z
Cancer Immunol Immunother; 1992; 35(5):331-4. PubMed ID: 1394337
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of Serratia marcescens extract in recurrent malignant astrocytoma.
Jaeckle KA; Mittelman A; Hill FH
J Clin Oncol; 1990 Aug; 8(8):1408-18. PubMed ID: 2199624
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of a new biological response modifier (ImuVert) in advanced prostate cancer.
Osborne CK; Craig JB; Klein K; Crawford ED; Turner J
Invest New Drugs; 1989 Jul; 7(2-3):243-5. PubMed ID: 2793381
[TBL] [Abstract][Full Text] [Related]
4. ImuVert activation of natural killer cytotoxicity and interferon gamma production via CD16 triggering.
Cunningham-Rundles S; Pearson FC
Int J Immunopharmacol; 1990; 12(6):589-98. PubMed ID: 2148737
[TBL] [Abstract][Full Text] [Related]
5. Clinical trial of Serratia marcescens extract and radiation therapy in patients with malignant astrocytoma.
Black KL; Ciacci JD; Ammirati M; Selch MT; Becker DP
J Clin Oncol; 1993 Sep; 11(9):1746-50. PubMed ID: 8394880
[TBL] [Abstract][Full Text] [Related]
6. Augmentation of natural killer cell activity by ImuVert: a biological response modifier derived from Serratia marcescens.
Warren RP; McCall CA; Urban RW
Mol Biother; 1989; 1(3):145-51. PubMed ID: 2690869
[TBL] [Abstract][Full Text] [Related]
7. A membrane vesicle/ribosome preparation from Serratia marcescens elicits peritoneal exudate cells expressing both tumoricidal and bactericidal activity.
McCall C; Weimer L; Baldwin S; Riches DW; Canono B; Campbell PA
Inflammation; 1992 Aug; 16(4):355-69. PubMed ID: 1526665
[TBL] [Abstract][Full Text] [Related]
8. ImuVert therapy in the treatment of recurrent malignant astrocytomas: nursing implications.
Cress NB; Owens BM; Hill FH
J Neurosci Nurs; 1991 Feb; 23(1):29-33. PubMed ID: 1826714
[TBL] [Abstract][Full Text] [Related]
9. Murine cytomegalovirus-inhibitory effects of ImuVert.
Sidwell RW; Smee DF; Warren RP; Huffman JH; Gilbert BJ; Burger RA; Pearson FC
Antiviral Res; 1993 Apr; 20(4):279-92. PubMed ID: 8387257
[TBL] [Abstract][Full Text] [Related]
10. Augmentation of ADCC and cytotoxic T-cell activity with ImuVert.
Warren RP; McCall CA; Urban RW
Mol Biother; 1989; 1(6):323-7. PubMed ID: 2610951
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of a biologic response modifier derived from Serratia marcescens: effects on feline macrophages and usefulness for the prevention and treatment of viremia in feline leukemia virus-infected cats.
Elmslie RE; Ogilvie GK; Dow SW; Gasper P; Hoover EA; Cooper MF; Pearson FC
Mol Biother; 1991 Dec; 3(4):231-8. PubMed ID: 1768375
[TBL] [Abstract][Full Text] [Related]
12. The influence of ImuVert, a biological response modifier, on the growth and ganglioside composition of murine neural tumors.
Cotterchio M; Seyfried TN
Mol Chem Neuropathol; 1993 Oct; 20(2):163-72. PubMed ID: 8297420
[TBL] [Abstract][Full Text] [Related]
13. Modulation of the immune response of Balb/c mice against Leishmania major by imuvert.
Taha SM; Tabbara KS
Int J Immunopharmacol; 1997 Aug; 19(8):443-9. PubMed ID: 9568550
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors.
Isambert N; Fumoleau P; Paul C; Ferrand C; Zanetta S; Bauer J; Ragot K; Lizard G; Jeannin JF; Bardou M
BMC Cancer; 2013 Apr; 13():172. PubMed ID: 23547558
[TBL] [Abstract][Full Text] [Related]
15. A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation.
Rinaldi DA; Kuhn JG; Burris HA; Dorr FA; Rodriguez G; Eckhardt SG; Jones S; Woodworth JR; Baker S; Langley C; Mascorro D; Abrahams T; Von Hoff DD
Cancer Chemother Pharmacol; 1999; 44(5):372-80. PubMed ID: 10501910
[TBL] [Abstract][Full Text] [Related]
16. A phase I clinical trial of recombinant interleukin-2 by periodic 24-hour intravenous infusions.
Creekmore SP; Harris JE; Ellis TM; Braun DP; Cohen II; Bhoopalam N; Jassak PF; Cahill MA; Canzoneri CL; Fisher RI
J Clin Oncol; 1989 Feb; 7(2):276-84. PubMed ID: 2783732
[TBL] [Abstract][Full Text] [Related]
17. Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors.
Margolin K; Morishima C; Velcheti V; Miller JS; Lee SM; Silk AW; Holtan SG; Lacroix AM; Fling SP; Kaiser JC; Egan JO; Jones M; Rhode PR; Rock AD; Cheever MA; Wong HC; Ernstoff MS
Clin Cancer Res; 2018 Nov; 24(22):5552-5561. PubMed ID: 30045932
[No Abstract] [Full Text] [Related]
18. Effect of prior cancer chemotherapy on human tumor-specific cytotoxicity in vitro in response to immunopotentiating biologic response modifiers.
Weisenthal LM; Dill PL; Pearson FC
J Natl Cancer Inst; 1991 Jan; 83(1):37-42. PubMed ID: 1984515
[TBL] [Abstract][Full Text] [Related]
19. Phase I evaluation of combination therapy with interleukin 2 and gamma-interferon.
Weiner LM; Padavic-Shaller K; Kitson J; Watts P; Krigel RL; Litwin S
Cancer Res; 1991 Aug; 51(15):3910-8. PubMed ID: 1906779
[TBL] [Abstract][Full Text] [Related]
20. Phase I and II trials of subcutaneously administered rIL-2, interferon alfa-2a, and fluorouracil in patients with metastatic renal carcinoma.
Olencki T; Peereboom D; Wood L; Budd GT; Novick A; Finke J; McLain D; Elson P; Bukowski RM
J Cancer Res Clin Oncol; 2001 May; 127(5):319-24. PubMed ID: 11355147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
